Physician profile
Ruchi Gupta
NPI 1558413302
$4,069.44
in general payments reported to CMS, 2019-2025
18 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $17.42 · 2021: $305 · 2022: $842 · 2023: $665 · 2024: $1,123 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.24 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,301.14 | 2020-2025 | |
| Janssen Biotech, INC. | $560.07 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $407.04 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $145.56 | 2022-2025 | Dupixent |
| Blueprint Medicines Corporation | $114.37 | 2025 | Ayvakit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.92 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $81.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $72.84 | 2024 | Voquezna |
| Celgene Corporation | $64.98 | 2022-2023 | Zeposia |
| Genzyme Corporation | $59.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.74 | 2023 | Cyltezo |
| Genentech USA, INC. | $21.54 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.27 | 2025 | Iqirvo |
| Ars Pharmaceuticals Operations, INC. | $19.64 | 2025 | Neffy |
| Braintree Laboratories, INC. | $17.56 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $17.35 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $14.64 | 2022 | |
| Amgen INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.